The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer

被引:105
作者
Rosen, Barry [1 ,2 ]
Laframboise, Stephane [1 ,2 ]
Ferguson, Sarah [1 ,2 ]
Dodge, Jason [1 ,2 ]
Bernardini, Marcus [1 ,2 ]
Murphy, Joan [1 ,2 ]
Segev, Yakir [1 ,2 ,3 ]
Sun, Ping [3 ]
Narod, Steven A. [3 ]
机构
[1] Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5G 2M9, Canada
[2] Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada
[3] Womens Coll Hosp, Womens Coll Res Inst, Familial Breast Canc Res Unit, Toronto, ON M5G 1N8, Canada
关键词
Ovarian cancer; Neoadjuvant chemotherapy; Intraperitoneal chemotherapy; GYNECOLOGIC-ONCOLOGY-GROUP; ADVANCED-STAGE OVARIAN; PHASE-III TRIAL; CYTOREDUCTION; PACLITAXEL; CISPLATIN;
D O I
10.1016/j.ygyno.2014.07.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. Women with advanced ovarian cancer are treated with chemotherapy either before (neoadjuvant) or after surgery (primary debulking). The goal is to leave no residual disease post-surgery; for women treated with primary debulking surgery this has been associated with an improvement in survival. It has not been shown that the survival advantage conferred by having no residual disease post-surgery is present for women who receive neoadjuvant chemotherapy. Methods. We reviewed the records of 326 women with stage Ilk or IV serous ovarian cancer. We determined if they received neoadjuvant chemotherapy or primary debullting surgery and we measured the extent of residual disease post-surgery. We estimated seven-year survival rates for women after various treatments. Results. Women who had neoadjuvant chemotherapy were more likely to have no residual disease than women who had primary debulking surgery (50.1% versus 41.5%; p = 0.03) but they experienced inferior seven-year survival (8.6% versus 41%; p < 0.0001). Among women who had primary debulking surgery, those with no residual disease had much better seven-year survival than women who had any residual disease (73.6% versus 21.0%; p < 0.0001). Women who had no residual disease after debulldng surgery and who received intraperitoneal chemotherapy had a seven-year survival of 90%. Conclusions. Neoadjuvant chemotherapy should be reserved for ovarian cancer patients who are not candidates for primary debulking surgery. Among women with no residual disease after primary debulking surgery, intraperitoneal chemotherapy extends survival. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:462 / 467
页数:6
相关论文
共 12 条
[1]   Aggressive surgical effort and improved survival in advanced-stage ovarian cancer [J].
Aletti, GD ;
Dowdy, SC ;
Gostout, BS ;
Jones, MB ;
Stanhope, CR ;
Wilson, TO ;
Podratz, KC ;
Cliby, WA .
OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) :77-85
[2]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[3]   Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis [J].
Bristow, Robert E. ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :1070-1076
[4]   An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) [J].
Chi, Dennis S. ;
Musa, Fernanda ;
Dao, Fanny ;
Zivanovic, Oliver ;
Sonoda, Yukio ;
Leitao, Mario M. ;
Levine, Douglas A. ;
Gardner, Ginger J. ;
Abu-Rustum, Nadeem R. ;
Barakat, Richard R. .
GYNECOLOGIC ONCOLOGY, 2012, 124 (01) :10-14
[5]   Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with "biological aggressiveness" and survival? [J].
Eisenkop, SM ;
Spirtos, NM .
GYNECOLOGIC ONCOLOGY, 2001, 82 (03) :435-441
[6]   Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2 [J].
McLaughlin, John R. ;
Rosen, Barry ;
Moody, Joel ;
Pal, Tuya ;
Fan, Isabel ;
Shaw, Patricia A. ;
Risch, Harvey A. ;
Sellers, Thomas A. ;
Sun, Ping ;
Narod, Steven A. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (02) :141-148
[7]   Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study [J].
Ozols, RF ;
Bundy, BN ;
Greer, BE ;
Fowler, JM ;
Clarke-Pearson, D ;
Burger, RA ;
Mannel, RS ;
DeGeest, K ;
Hartenbach, EM ;
Baergen, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3194-3200
[8]  
SKIPPER HE, 1978, CANCER-AM CANCER SOC, V41, P936, DOI 10.1002/1097-0142(197803)41:3<936::AID-CNCR2820410322>3.0.CO
[9]  
2-B
[10]   Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges? [J].
Vergote, Ignace ;
Leunen, Karin ;
Amant, Frederic .
GYNECOLOGIC ONCOLOGY, 2012, 124 (01) :1-2